In ovarian cancer models, combining cystinase with immune checkpoint inhibitors, specifically PD-L1 blockers, has been shown to amplify T cell-driven anti-tumor responses, resulting in enhanced tumor suppression (Xiong et al., 2021). The gene discussed is CD274; the disease is neoplasm.